Icariin to Prevent Corticosteroid-related Memory Changes

Study ID
STU 102012-052

Cancer Related

Healthy Volunteers

Study Sites

  • UT Southwestern-Other
  • UT Southwestern-Clinical Translational Research Center (CTRC)
  • Zale Lipshy University Hospital

Collette Bice

Principal Investigator
Edson Brown, M.D., Ph.D.


The study will be a pharmakinetic and safety/tolerability study for 20% icariin horny goat weed. 5 dose levels will be studied: 100 mg icariin, 200 mg, 400 mg, 840 mg, and 1680 mg QD for 5 days. Dosing will start at 100 mg for the first 6 participants. if the dose is deemed safe and well tolerated, the next higher dose will be administered to 6 new participants. The study will be a randomized, placebo-controlled trial.

Time to peak plasma concentration and halflife of icariin will be determined from the blood data. Safety and tolerability, including mood symptoms, will be assessed as well.

Participant Eligibility

* Healthy men and women age 18-50 years

* Education of >= 12 years and baseline RAVLT total words recalled score >= 35 (normal baseline memory)

* BMI between 18.5-30 (not underweight or obese)

* No medication changes within 30 days of baseline visit

* The ability to read and speak English.